Literature DB >> 33236884

Residence Time-Extended Nanoparticles by Magnetic Field Improve the Eradication Efficiency of Helicobacter pylori.

Shu-Jyuan Yang1, Chung-Huan Huang1, Jyh-Chin Yang2, Chung-Hao Wang3, Ming-Jium Shieh1,4.   

Abstract

Helicobacter pylori infection is one of the leading causes of several gastroduodenal diseases, such as gastritis, peptic ulcer, and gastric cancer. In fact, H. pylori eradication provides a preventive effect against the incidence of gastric cancer. Amoxicillin is a commonly used antibiotic for H. pylori eradication. However, due to its easy degradation by gastric acid, it is necessary to administer it in a large dosage and to combine it with other antibiotics. This complexity and the strong side effects of H. pylori eradication therapy often lead to treatment failure. In this study, the chitosan/poly (acrylic acid) particles co-loaded with superparamagnetic iron oxide nanoparticles and amoxicillin (SPIO/AMO@PAA/CHI) are used as drug nano-carriers for H. pylori eradication therapy. In vitro and in vivo results show that the designed SPIO/AMO@PAA/CHI nanoparticles are biocompatible and could retain the biofilm inhibition and the bactericidal effect of amoxicillin against H. pylori. Moreover, the mucoadhesive property of chitosan allows SPIO/AMO@PAA/CHI nanoparticles to adhere to the gastric mucus layer and rapidly pass through the mucus layer after exposure to a magnetic field. When PAA is added, it competes with amoxicillin for chitosan, so that amoxicillin is quickly and continuously released between the mucus layer and the gastric epithelium and directly acts on H. pylori. Consequently, the use of this nano-carrier can extend the drug residence time in the stomach, reducing the drug dose and treatment period of H. pylori eradication therapy.

Entities:  

Keywords:  Helicobacter pylori; amoxicillin; chitosan; magnetic nanoparticle; poly(acrylic acid)

Mesh:

Substances:

Year:  2020        PMID: 33236884     DOI: 10.1021/acsami.0c13101

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  6 in total

Review 1.  Biofilms: Formation, Research Models, Potential Targets, and Methods for Prevention and Treatment.

Authors:  Yajuan Su; Jaime T Yrastorza; Mitchell Matis; Jenna Cusick; Siwei Zhao; Guangshun Wang; Jingwei Xie
Journal:  Adv Sci (Weinh)       Date:  2022-08-28       Impact factor: 17.521

Review 2.  New Advances in Nano-Drug Delivery Systems: Helicobacter pylori and Gastric Cancer.

Authors:  Xiang Zhu; Tingting Su; Shouhua Wang; Huiqing Zhou; Weibin Shi
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

3.  Transcriptome Analysis of the Response of Mature Helicobacter pylori Biofilm to Different Doses of Lactobacillus salivarius LN12 with Amoxicillin and Clarithromycin.

Authors:  Fang Jin; Hong Yang
Journal:  Antibiotics (Basel)       Date:  2022-02-17

4.  Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability.

Authors:  Shu-Jyuan Yang; Chih-Hao Chang; Tai-Horng Young; Chung-Hao Wang; Tzu-Hao Tseng; Man-Ling Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 5.  Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations.

Authors:  Roberto Grosso; M-Violante de-Paz
Journal:  Pharmaceutics       Date:  2022-06-24       Impact factor: 6.525

Review 6.  Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives.

Authors:  Yongkang Lai; Wei Wei; Yiqi Du; Jie Gao; Zhaoshen Li
Journal:  Gut Microbes       Date:  2022 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.